menu search

HIMS / HIMS: Great Buying Opportunity

HIMS: Great Buying Opportunity
In 2018, Hims & Hers generated $27M and three years later it's already increased revenues by 10-fold, yet the company's trading at less than its 2019 valuation. Hims & Hers Health is a rapidly growing telehealth company that's disrupting the $4T US healthcare industry with its modern platform. Read More
Posted: Feb 8 2022, 09:30
Author Name: Seeking Alpha
Views: 111858

HIMS News  

Hims & Hers: A Promising Company With Resolvable Challenges

By Seeking Alpha
November 2, 2023

Hims & Hers: A Promising Company With Resolvable Challenges

While HIMS showcases robust performance, its ability to navigate and mitigate associated risks will be pivotal in securing its future success. Major r more_horizontal

Hims & Hers: Specialization Is The Secret To Great Growth

By Seeking Alpha
October 24, 2023

Hims & Hers: Specialization Is The Secret To Great Growth

Hims & Hers Health offers personalized and customized telehealth services, specializing in niche treatments for hair loss, erectile dysfunction, skinc more_horizontal

Is Hims & Hers Health Stock a Buy Now?

By The Motley Fool
October 3, 2023

Is Hims & Hers Health Stock a Buy Now?

Hims & Hers is cutting prices, but profit margins are rising. The company is cash flow positive, with plenty of cash on the balance sheet. more_horizontal

Hims & Hers Health: Risks Remain, But Upgrading To Buy

By Seeking Alpha
September 20, 2023

Hims & Hers Health: Risks Remain, But Upgrading To Buy

Hims & Hers reported strong earnings and raised its full-year guidance, but its stock continues to decline. Hims & Hers is focusing on personalization more_horizontal

Hims & Hers: Myopic Shorts, Absurdly Cheap

By Seeking Alpha
September 20, 2023

Hims & Hers: Myopic Shorts, Absurdly Cheap

Hims & Hers Health, Inc. is rapidly growing and becoming more profitable, making it a cheaply valued stock with minimal risk. A recent short report qu more_horizontal

The Market Is Wrong On Hims & Hers Health

By Seeking Alpha
September 17, 2023

The Market Is Wrong On Hims & Hers Health

Hims & Hers managed to grow revenue every year by at least 80%. However, it's still trading below its initial price when became publicly traded via SP more_horizontal

Is This Underrated SPAC Deal Stock a No-Brainer Buy?

By The Motley Fool
September 6, 2023

Is This Underrated SPAC Deal Stock a No-Brainer Buy?

Hims & Hers Health went public through a SPAC merger a couple of years ago. Since then, the stock is down 60%. more_horizontal

Hims & Hers: Buying With Both Fists (Double Rating Upgrade)

By Seeking Alpha
August 21, 2023

Hims & Hers: Buying With Both Fists (Double Rating Upgrade)

Hims & Hers Health reported a strong Q2 and raised guidance, but the stock has sold off sharply. The company is expanding into new product categories more_horizontal


Search within

Pages Search Results: